Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)
3.760
+0.070 (1.90%)
At close: Feb 13, 2026
HKG:2563 Revenue
Beijing Biostar Pharmaceuticals had revenue of 7.39M CNY in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to 53.53M. In the year 2024, Beijing Biostar Pharmaceuticals had annual revenue of 71.87M with 7.85% growth.
Revenue (ttm)
53.53M CNY
Revenue Growth
+7.85%
P/S Ratio
23.37
Revenue / Employee
408.63K CNY
Employees
131
Market Cap
1.37B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 71.87M | 5.23M | 7.85% |
| Dec 31, 2023 | 66.64M | 33.82M | 103.03% |
| Dec 31, 2022 | 32.82M | -38.24M | -53.82% |
| Dec 31, 2021 | 71.06M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 491.34M |
| Cutia Therapeutics | 274.31M |
| JW (Cayman) Therapeutics Co. | 194.77M |
| Wuhan YZY Biopharma | 163.65M |
| CANbridge Pharmaceuticals | 68.55M |
| Brii Biosciences | 31.53M |
| Kintor Pharmaceutical | 12.04M |
| Transcenta Holding | 10.31M |